loperamide has been researched along with Lung Neoplasms in 3 studies
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diarrhea is a common adverse event of docetaxel with 20%-40% of incidence and severe diarrhea occurs in 5%-6%." | 5.39 | Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report. ( Kim, HK; Kim, MJ; Lee, HY; Lee, YH, 2013) |
| " Treatment with 100 microM buprenorphine, a representative analgesic, induced cell death of human carcinomas, such as A549 (squamous epithelial cell of lung cancer), MCF-7 (breast cancer) and N417 (small cell of lung cancer), but not in KATO III (gastric cancer) cells as evaluated by alamar blue assay." | 3.70 | Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells. ( Iwamura, T; Tokuyama, S; Ueda, H; Yoshida, A, 2000) |
| "Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for first-line treatment of non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations." | 1.56 | Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells. ( Cho, WCS; To, KKW; Tong, CWS; Wu, MMX; Yan, VW, 2020) |
| "Diarrhea is a common adverse event of docetaxel with 20%-40% of incidence and severe diarrhea occurs in 5%-6%." | 1.39 | Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report. ( Kim, HK; Kim, MJ; Lee, HY; Lee, YH, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tong, CWS | 1 |
| Wu, MMX | 1 |
| Yan, VW | 1 |
| Cho, WCS | 1 |
| To, KKW | 1 |
| Lee, HY | 1 |
| Lee, YH | 1 |
| Kim, MJ | 1 |
| Kim, HK | 1 |
| Yoshida, A | 1 |
| Tokuyama, S | 1 |
| Iwamura, T | 1 |
| Ueda, H | 1 |
3 other studies available for loperamide and Lung Neoplasms
| Article | Year |
|---|---|
Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
Topics: Animals; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carci | 2020 |
Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Drug Therapy, Combination; Hum | 2013 |
Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells.
Topics: Analgesics, Opioid; Apoptosis; Breast Neoplasms; Buprenorphine; Carcinoma, Small Cell; Carcinoma, Sq | 2000 |